G'day from San Jose. We couldn't be more delighted to be here at this gathering of the best and brightest in synthetic biology to share what's happening with eXoZymes. I have been looking forward to this day to announce that the first spin-out company is happening. We are spinning out NCTx, a company focusing on the small molecule called NCT. eXoZymes' strategy is nutraceuticals that has pharmaceutical potential. NCTx is a perfect example of our strategy of taking a small molecule natural compound and turning it into an exozyme biosolution that allows people to have access to a compound that otherwise was very difficult or impossible to manufacture. We are announcing that we're developing a target NCT, N-trans-caffeoyltyramine, and the spin-out of our company called NCTx for the purposes of continuing the commercialization of this wonderful ingredient. N-trans-caffeoyltyramine has already been shown in various research papers to have positive effects against fatty liver metabolism, gut barrier function, and mitochondrial health. Giving us that inspiration that this is an ingredient that will have real-world applications in food, nutrition, where consumers want to eat healthier, and nutrition, where consumers want to be able to eat healthier, but also in pharmaceuticals. And there's another element here where AI comes into play, is because we're not just designing the process to meet the quality and volume needs of these two markets, but we're also designing analogs around NCT to offer our clinical development partners even further diversity to work with, to find molecules that may have even improved function against those future application areas they want to meet. With this exciting development, bringing our company to the first commercialization opportunity of our core technology, we're also starting to look for partners. Partners that would like to work on NCT together with us, but also partners that by looking at the NCT business opportunity, realizes that they know of a small molecule, a natural compound that they would like to bring to market. What really, really impresses me is how quickly the team has been able to move from idea to proof of concept in about six weeks, and then coming together with conviction that this is a target we really want to commercialize, and moving into a spin-out in a matter of 12 weeks. This is the conviction pin that our industry needs to be able to move with expediency and urgency towards meeting the demands of our future markets with the technology in our hands today. When we look at the potential of NCT and how fast, how cheap and precise we have been able to build that, we get very excited about the many other things we will build together with partners over the coming years. Once again, we're super excited to be here and to be sharing this story with the world, with our colleagues in the world of SynBioBeta.